95 Greene St. in Jersey City — File photo/Courtesy: Thor Equities Group
By Joshua Burd
Thor Equities Group has signed a new deal at its life sciences building in Jersey City, leasing nearly 30,000 square feet of lab-ready space to a nonprofit biotechnology organization.
According to CBRE, which represented the occupier, IAVI will relocate its Vaccine Design and Development Lab to 95 Greene St. from the Brooklyn Army Terminal. The former International AIDS Vaccine Initiative joins several other health care and life sciences tenants at the 350,000-square-foot building, following Thor’s acquisition of the property in 2020 and subsequent plan to create a hub of turnkey lab and research space.
John Isaacs, Joseph DeRosa, Conor Dolan and others from CBRE represented IAVI in the 29,782-square-foot deal. JLL’s Blake Goodman, Bob Ryan, Dan Loughlin, Craig Eisenhardt, John Cahill and Dan Spero are the property’s leasing team.
“The DDL team looks forward to joining the vibrant life sciences community at 95 Greene Street,” said Christopher L. Parks, associate vice president of viral vaccines and head of the IAVI DDL. “This upgraded, fit-for-purpose lab space is tailored to the DDL’s unique infrastructure needs as a leader in vaccine R&D and in global health research. We are poised to strengthen connections and accelerate progress with partners across the New York and New Jersey life sciences communities with our new footprint in Jersey City.”
In a news release, CBRE said IAVI develops vaccines and antibodies for HIV, tuberculosis and emerging infectious diseases. Its design and development lab serves as the preclinical development hub for its emerging infectious diseases vaccine portfolio, using science that’s similar to that of a licensed Ebola vaccine to design treatments for priority pathogens including Ebola Sudan, Marburg, Lassa and COVID-19.
